Optimising PrEP Uptake and Use in Peru: No Time to Lose!
Document Type
Article
Publication Date
2024
Digital Object Identifier (DOI)
https://doi.org/10.1016/S2352-3018(24)00038-9
Abstract
In May, 2010, results of the multicountry iPrEx study were released: daily oral co-formulated emtricitabine and tenofovir disoproxil fumarate effectively prevented HIV infection among men who have sex with men (MSM) and transgender women.1 The new intervention, pre-exposure prophylaxis (PrEP), was approved by the US Food and Drug Administration in 2012, and a broad global scale-up was anticipated. In Peru, where more than half of all iPrEx participants were enrolled, PrEP was urgently needed, and in 2016 its use was approved by the Ministry of Health; however, access was limited to demonstration studies (that began in 2017) or unsubsidised private sector purchases, and uptake was poor. By mid-2023, according to UNAIDS data, less than 3000 people had initiated PrEP, and in September, 2023, only about 0·9% (approximately 800 people) of the estimated 90 000 who could benefit from PrEP, were receiving it.2 Meanwhile, new HIV infections among adults (aged ≥15 years) in Peru have increased by 52% since 2012.
Was this content written or created while at USF?
Yes
Citation / Publisher Attribution
The Lancet HIV, v. 11, issue 4, p. e204-e206
Scholar Commons Citation
Menacho, Luis; Konda, Kelika A.; Lecca, Leonid; Cabello, Robinson; Lankowski, Alexander; Benites, Carlos; Gallardo-Cartagena, Jorge A.; Duerr, Ann; Sánchez, Jorge; and Galea, Jerome T., "Optimising PrEP Uptake and Use in Peru: No Time to Lose!" (2024). Social Work Faculty Publications. 289.
https://digitalcommons.usf.edu/sok_facpub/289
